You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2024

Investigational Drug Information for HQP1351

✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for HQP1351?

HQP1351 is an investigational drug.

There have been 9 clinical trials for HQP1351. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2022.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, and Leukemia. The leading clinical trial sponsors are Ascentage Pharma Group Inc., HealthQuest Pharma Inc., and Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

There are two US patents protecting this investigational drug and twenty-nine international patents.

Recent Clinical Trials for HQP1351
Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.Shenzhen Second People's HospitalPhase 3
Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCTGuangdong Second Provincial General HospitalPhase 2
Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCTNanfang Hospital of Southern Medical UniversityPhase 2

See all HQP1351 clinical trials

Clinical Trial Summary for HQP1351

Top disease conditions for HQP1351
Top clinical trial sponsors for HQP1351

See all HQP1351 clinical trials

US Patents for HQP1351

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
HQP1351 ⤷  Sign Up Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences (Guangzhou, Guangdong, CN) ⤷  Sign Up
HQP1351 ⤷  Sign Up Proteolysis targeting chimera compounds and methods of preparing and using same Yale University (New Haven, CT) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.